| Authors: |
McKernan RM; Chair of the Scientific Advisory Board of the Dementia Goals Programme, Operating Partner of SV Health Investors, London, UK., Rowe JB; Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK., John S; Informatics & Predictive Sciences, Bristol Myers Squibb, Cambridge, Massachusetts, USA., Karran E; University College London, London, UK.; Vannin Neuropharma Consulting Ltd, Canterbury, UK., Fachim HA; Medicines Discovery Catapult, Macclesfield, UK., Imarisio S; Medicines Discovery Catapult, Macclesfield, UK., Long R; Senior Advisor Consultant, Gates Ventures, Kirkland, USA., Teunissen C; Department of Laboratory Medicine, Neurochemistry Laboratory, Amsterdam UMC, Amsterdam, the Netherlands., Slight SP; School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK., Mummery C; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK., Hardy J; Deputy-chair of the Scientific Advisory Board of the Dementia Goals Programme, Department of Neurodegenerative Disease, UK Dementia Research Institute Centre at University College London, London, UK. |
